ArticleProteomics. Clinical applications2008
Sera proteomic biomarker profiling in HIV-1 infected subjects with cognitive impairment.
Article in Proteomics. Clinical applications, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Article
- Cerebrospinal Fluid Ceruloplasmin, Haptoglobin, and Vascular Endothelial Growth Factor Are Associated with Neurocognitive Impairment in Adults with HIV Infection.Molecular neurobiology · 2019Article
- Modifications in acute phase and complement systems predict shifts in cognitive status of HIV-infected patients.AIDS (London, England) · 2017Article
- Proteomics, biomarkers, and HIV-1: A current perspective.Proteomics. Clinical applications · 2016Review
- Macrophage secretome from women with HIV-associated neurocognitive disorders.Proteomics. Clinical applications · 2016Article
- Transition from identity to bioactivity-guided proteomics for biomarker discovery with focus on the PF2D platform.Proteomics. Clinical applications · 2016Review
- Proteomic analysis of saliva in HIV-positive heroin addicts reveals proteins correlated with cognition.PloS one · 2014Article
- Comparison of 4-plex to 8-plex iTRAQ quantitative measurements of proteins in human plasma samples.Journal of proteome research · 2012Article
- Changes in the plasma proteome follows chronic opiate administration in simian immunodeficiency virus infected rhesus macaques.Drug and alcohol dependence · 2012Article
- Article
- Immunoreactivity of anti-gelsolin antibodies: implications for biomarker validation.Journal of translational medicine · 2010Article
- Plasma proteomic analysis of simian immunodeficiency virus infection of rhesus macaques.Journal of proteome research · 2010Article
- Proteomic and metabolomic strategies to investigate HIV-associated neurocognitive disorders.Genome medicine · 2010Article
- Biomarker discovery and clinical proteomics.Trends in analytical chemistry : TRAC · 2010Article
- Quantitative plasma proteomic profiling identifies the vitamin E binding protein afamin as a potential pathogenic factor in SIV induced CNS disease.Journal of proteome research · 2010Article
- Biomarkers of HIV-1-associated neurocognitive disorders: challenges of proteomic approaches.Biomarkers in medicine · 2009Article
- Biomarkers of HIV-1 associated dementia: proteomic investigation of sera.Proteome science · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
Abstract
HIV-1 infection of the brain commonly leads to cognitive impairments (CIs). In its most severe form, HIV-1 associated dementia (HAD) is associated with advanced immune suppression and debilitating loss of memory, behavioral, and motor functions. Despite significant research activities, diagnosis remains one of exclusion. Bioimaging, neuropsychological testing, and viral and immune biomarkers serve to support but not define a diagnosis of HIV-1 associated CI. This is timely and required as brain injury triggered by HIV-1 can be controlled, in part, by antiretroviral medicines. The recent development of proteomics has opened new ways to study viral-host interactions which may provide new insight into treatment and disease monitoring. To this end, we developed a proteomics platform for HIV-1 associated CI biomarker discovery and used it to perform a pilot study for sera-associated HAD proteins. A 2-DE map of a serum proteome was focused on differentially expressed proteins. Differential expression of two proteins was validated by Western blot tests identifying afamin and ceruloplasmin as a potential biomarkers for CI associated with advanced HIV-1 infection.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.